EVO ICL has moved from a niche refractive option to a meaningful share of the U.S. market over the past several years. This quarterly report tracks adoption trends, patient profile, and how EVO ICL’s growth compares to adjacent procedures like LASIK and RLE.
Q2 2026 continued a multi-quarter growth trend, with adoption concentrated among patients in their 20s and 30s seeking a reversible, non-corneal alternative to LASIK — a meaningfully younger patient base than RLE’s, which skews toward presbyopia-driven demand in patients over 45.
Referring optometrist awareness has been cited industry-wide as a significant factor in EVO ICL’s growth, alongside increasing surgeon training availability. This report will be updated quarterly going forward.
Suggested excerpt: “Quarterly tracking of EVO ICL adoption trends, patient profile, and growth relative to LASIK and RLE.”
Related links to include: Procedure Mix: LASIK vs. RLE vs. EVO ICL